药物诱导性肝损伤与肠道微生物群之间的相互作用:全面概述
Guolin Li1, Yifu Hou2, Changji Zhang1
1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; Department of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
概括
肠道微生物群通过增加透性和炎症等机制影响药物诱导性肝损伤 (DILI). 准肠道微生物群为DILI治疗提供了一个有希望的新途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 药物诱导性肝损伤 (DILI) 是一个重大临床挑战,影响患者健康和药物开发.
- 新兴研究强调肠道微生物群和DILI之间存在强烈的相关性.
- 连接肠道微生物群与DILI的确切机制尚不完全理解.
研究的目的:
- 审查肠道微生物群和常见的肝毒药物之间的关联.
- 阐明肠道微生物群对DILI病原发生的潜在机制.
- 为DILI-肠道微生物群相互作用提供全面的参考.
主要方法:
- 对调查肠道微生物群和DILI的研究进行文献综述.
- 分析包括肠道透性,代谢物恒温,炎症和氧化应激等机制.
- 检查与各种药物类别相关的DILI病例.
主要成果:
- 在与抗生素,精神药物,乙氨基,抗结核药物和抗甲状腺药物相关的DILI病例中观察到肠道微生物群的改变.
- 特定的肠道微生物组成和丰度与DILI严重程度相关.
- 建议的机制包括增加肠道透性,破坏代谢物平衡,增强炎症/氧化应激.
结论:
- 肠道微生物群在DILI的发病过程中起着至关重要的作用.
- 肠道微生物群代表了管理DILI的潜在治疗点.
- 对于新的治疗策略,对DILI-肠道微生物群轴的进一步研究是有必要的.
更多相关视频
相关概念视频
Factors Influencing Drug Absorption: Disease States and Pharmacology
497
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
497
Drug Absorption: Factors Affecting GI Absorption
3.9K
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
3.9K
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Hepatic Drug Clearance: Role of Transporters
54
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
54
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K
Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166


